Logo - Réseau Parkinson Québec
Réseau Parkinson Québec
fr

Publications

Please find here all the publications in which the Quebec Parkinson Network and its members are involved.

2025

  • Cognition and obstructive sleep apnea in Parkinson’s disease: randomized controlled trial of positive airway pressure (COPE-PAP trial). Lajoie AC, Lafontaine AL, Kimoff RJ, Benedetti A, Robinson AR, Létourneau M, Crane J, Scanga A, Noel F, Kaminska M. Sleep. 2025 Feb 13:zsaf038. doi: 10.1093/sleep/zsaf038. Epub ahead of print. PMID: 39945727.
  • Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson’s Disease. Sun S, Madge V, Djordjevic J, Gagnon JF, Collins DL, Dagher A, Sharp M. Mov Disord. 2025 May;40(5):844-854. doi: 10.1002/mds.30148. Epub 2025 Feb 13. PMID: 39945211; PMCID: PMC12089896.
  • LRRK2 rare-variant per-domain genetic burden in Parkinson’s Disease: association confined to the kinase domain. Parlar SC, Senkevich K, Yu E, Ruskey JA, Ahmad J, Asayesh F, Spiegelman D, Waters C, Monchi O, Dauvilliers Y, Dupré N, Greenbaum L, Hassin-Baer S, Miliukhina I, Timofeeva A, Emelyanov A, Pchelina S, Alcalay RN, Fon EA, Trempe JF, Gan-Or Z. NPJ Parkinsons Dis. 2025 Apr 29;11(1):102. doi: 10.1038/s41531-025-00934-z. PMID: 40301370; PMCID: PMC12041573.
  • Associations between neuromelanin depletion and cortical rhythmic activity in Parkinson’s disease. Wiesman AI, Madge V, Fon EA, Dagher A, Collins DL, Baillet S; PREVENT-AD Research Group and Quebec Parkinson Network. Brain. 2025 Mar 6;148(3):875-885. doi: 10.1093/brain/awae295. PMID: 39282945; PMCID: PMC11884654.

2024

  • The neurophysiological brain-fingerprint of Parkinson’s disease. da Silva Castanheira J, Wiesman AI, Hansen JY, Misic B, Baillet S; PREVENT-AD Research Group; Quebec Parkinson Network. EBioMedicine. 2024 Jul;105:105201. doi: 10.1016/j.ebiom.2024.105201. Epub 2024 Jun 21. PMID: 38908100; PMCID: PMC11253223.
  • Oral Levodopa Therapy, Vitamin B6 and Peripheral Neuropathy: A Cross-Sectional Observational Study. Déry C, Buchmann C, Labrecque G, Caron V, Simonyan D, Blais M, Bouchard M, Dupré N. Mov Disord Clin Pract. 2025 Jan;12(1):120-122. doi: 10.1002/mdc3.14243. Epub 2024 Oct 23. PMID: 39441018; PMCID: PMC11736868.
  • The Effect of Different Types of Exercise on Sleep Quality and Architecture in Parkinson Disease: A Single-Blinded Randomized Clinical Trial Protocol. Cristini J, Potvin-Desrochers A, Seo F, Dagher A, Postuma RB, Rosa-Neto P, Carrier J, Amara AW, Steib S, Paquette C, Roig M. Phys Ther. 2024 Jan 1;104(1):pzad073. doi: 10.1093/ptj/pzad073. PMID: 37354450; PMCID: PMC10776310.
  • Real-time auditory feedback for improving gait and walking in people with Parkinson’s disease: a pilot and feasibility trial. Mayo NE, Mate KKV, Fellows LK, Morais JA, Sharp M, Lafontaine AL, Hill ET, Dawes H, Sharkh AA. Pilot Feasibility Stud. 2024 Aug 27;10(1):115. doi: 10.1186/s40814-024-01542-z. PMID: 39192343; PMCID: PMC11348556.
  • Parkinson’s disease CA2-CA3 hippocampal atrophy is accompanied by increased cholinergic innervation in patients with normal cognition but not in patients with mild cognitive impairment. Legault-Denis C, Aumont É, Onuska KM, Schmitz TW, Bussy A, Chakravarty M, Soucy JP, Bédard MA. Brain Imaging Behav. 2024 Aug;18(4):783-793. doi: 10.1007/s11682-024-00872-z. Epub 2024 Mar 13. PMID: 38478257.
  • Eye movement function captured via an electronic tablet informs on cognition and disease severity in Parkinson’s disease. Koch NA, Voss P, Cisneros-Franco JM, Drouin-Picaro A, Tounkara F, Ducharme S, Guitton D, de Villers-Sidani É. Sci Rep. 2024 Apr 20;14(1):9082. doi: 10.1038/s41598-024-59750-9. PMID: 38643273; PMCID: PMC11032372.
  • Sleep spindle density and temporal clustering are associated with sleep-dependent memory consolidation in Parkinson’s disease. Lahlou S, Kaminska M, Doyon J, Carrier J, Sharp M. J Clin Sleep Med. 2024 Jul 1;20(7):1153-1162. doi: 10.5664/jcsm.11080. PMID: 38427318; PMCID: PMC11217638.
  • Exploring obstructive sleep apnea and sleep architecture in Parkinson’s disease motor subtypes. Scanga A, Benedetti A, Kimoff RJ, Lafontaine AL, Robinson A, Gingras M, Kaminska M. Parkinsonism Relat Disord. 2024 May;122:106064. doi: 10.1016/j.parkreldis.2024.106064. Epub 2024 Feb 23. PMID: 38432022.

2023

  • Structural and neurophysiological alterations in Parkinson’s disease are aligned with cortical neurochemical systems. Wiesman AI, da Silva Castanheira J, Fon EA, Baillet S; PREVENT-AD Research Group; Quebec Parkinson Network. medRxiv [Preprint]. 2023 Apr 5:2023.04.04.23288137. doi: 10.1101/2023.04.04.23288137. Update in: Ann Neurol. 2024 Apr;95(4):802-816. doi: 10.1002/ana.26871. PMID: 37066346; PMCID: PMC10104211.
  • Alterations of Cortical Structure and Neurophysiology in Parkinson’s Disease Are Aligned with Neurochemical Systems. Wiesman AI, da Silva Castanheira J, Fon EA, Baillet S; PREVENT‐AD Research Group; Quebec Parkinson Network. Ann Neurol. 2024 Apr;95(4):802-816. doi: 10.1002/ana.26871. Epub 2024 Jan 12. PMID: 38146745; PMCID: PMC11023768.
  • Adverse and compensatory neurophysiological slowing in Parkinson’s disease. Wiesman AI, da Silva Castanheira J, Degroot C, Fon EA, Baillet S; PREVENT-AD Research Group; Network QP. Prog Neurobiol. 2023 Dec;231:102538. doi: 10.1016/j.pneurobio.2023.102538. Epub 2023 Oct 11. PMID: 37832713; PMCID: PMC10872886.
  • Cognitive Interviewing to Develop a New Health-Related Quality of Life Measure for Parkinson’s Disease: The Preference-Based Parkinson’s Disease Index (PB-PDI). Na E, Teshler L, Malouka S, Mayo NE, Bouchard V, Barbier A, Kuspinar A. J Patient Exp. 2023 Nov 28;10:23743735231211781. doi: 10.1177/23743735231211781. PMID: 38033912; PMCID: PMC10685756.
  • Aberrant neurophysiological signaling associated with speech impairments in Parkinson’s disease. Wiesman, A. I., Villeneuve, S., Donhauser, P. W., Degroot, C., Diab, S., Kousaie, S., Fon, E. A., Klein, D., Baillet, S., PREVENT-AD Research Group, Quebec Parkinson Network. 2023. Npj Parkinson’s Disease, 9(1), 61–61. https://doi.org/10.1038/s41531-023-00495-z
  • Levodopa alters resting-state functional connectivity more selectively in Parkinson’s disease with freezing of gait. Potvin-Desrochers, A., Atri, A., Moreno, A. M., Paquette, C. 2023. The European Journal of Neuroscience, 57(1), 163–177. https://doi.org/10.1111/ejn.15849
  • Genome-wide contribution of common short-tandem repeats to parkinson’s disease genetic risk. Bustos, B. I., Billingsley, K., Blauwendraat, C., Gibbs, J. R., Gan-Or, Z., Krainc, D., Singleton, A. B., Lubbe, S. J.; International Parkinson’s Disease Genomics Consortium (IPDGC). 2023. Brain: A Journal of Neurology, 146(1), 65–74. https://doi.org/10.1093/brain/awac301
  • GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease. Senkevich K, Zorca CE, Dworkind A, Rudakou U, Somerville E, Yu E, Ermolaev A, Nikanorova D, Ahmad J, Ruskey JA, Asayesh F, Spiegelman D, Fahn S, Waters C, Monchi O, Dauvilliers Y, Dupré N, Greenbaum L, Hassin-Baer S, Grenn FP, Chiang MSR, Sardi SP, Vanderperre B, Blauwendraat C, Trempe JF, Fon EA, Durcan TM, Alcalay RN, Gan-Or Z. Brain. 2023 May 2;146(5):1859-1872. doi: 10.1093/brain/awac413. PMID: 36370000; PMCID: PMC10151180.
  • Association of rare variants in ARSA with Parkinson’s disease. Senkevich, K., Beletskaia, M., Dworkind, A., Yu, E., Ahmad, J., Ruskey, J. A., Asayesh, F., Spiegelman, D., Fahn, S., Waters, C., Monchi, O., Dauvilliers, Y., Dupré, N., Greenbaum, L., Hassin-Baer, S., Nagornov, I., Tyurin, A., Miliukhina, I., Timofeeva, A., … Gan-Or, Z. 2023. Movement Disorders : Official Journal of the Movement Disorder Society, 38(10), 1806–1812. https://doi.org/10.1002/mds.29521
  • Item selection for a new health-related quality of life measure for Parkinson’s disease: the preference-based parkinson’s disease index (pb-pdi). Malouka, S., Teshler, L., Mayo, N., Beauchamp, M., Richardson, J., Kuspinar, A. 2023. Neurology Research International, 2023, 6559857–6559857. https://doi.org/10.1155/2023/6559857

2022

  • Dopaminergic medication increases motivation to exert cognitive control by reducing subjective effort costs in Parkinson’s patients. Bogdanov, M., LoParco, S., Otto, A. R., & Sharp, M. 2022. Neurobiology of learning and memory, 193, 107652. https://doi.org/10.1016/j.nlm.2022.107652
  • Goal management training and psychoeducation / mindfulness for treatment of executive dysfunction in parkinson’s disease: a feasibility pilot trial. Giguère-Rancourt, A., Plourde, M., Racine, E., Couture, M., Langlois, M., Dupré, N., Simard, M. 2022. Plos One, 17(2), 0263108. https://doi.org/10.1371/journal.pone.0263108
  • 17q21.31 sub-haplotypes underlying h1-associated risk for parkinson’s disease are associated with lrrc37a/2 expression in astrocytes. Bowles, K. R., Pugh, D. A., Liu, Y., Patel, T., Renton, A. E., Bandres-Ciga, S., Gan-Or, Z., Heutink, P., Siitonen, A., Bertelsen, S., Cherry, J. D., Karch, C. M., Frucht, S. J., Kopell, B. H., Peter, I., Park, Y. J., Charney, A., Raj, T., Crary, J. F., … International Parkinson’s Disease Genomics Consortium (IPDGC). 2022.  Molecular Neurodegeneration, 17(1), 48–48. https://doi.org/10.1186/s13024-022-00551-x

2021

  • Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson’s disease. Neuropharmacology. Kwan C, Frouni I, Nuara SG, Belliveau S, Kang W, Hamadjida A, Bedard D, Beaudry F, Panisset M, Gourdon JC, Huot P.  2021;186:108465. 
  • Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations. Rudakou U, Yu E, Krohn L, Ruskey JA, Asayesh F, Dauvilliers Y, Spiegelman D, Greenbaum L, Fahn S, Waters CH, Dupre N, Rouleau GA, Hassin-Baer S, Fon EA, Alcalay RN, Gan-Or Z. Brain. 2021;144(2):462-72. 
  • Investigating the relationship between the SNCA gene and cognitive abilities in idiopathic Parkinson’s disease using machine learning. Ramezani M, Mouches P, Yoon E, Rajashekar D, Ruskey JA, Leveille E, Martens K, Kibreab M, Hammer T, Kathol I, Maarouf N, Sarna J, Martino D, Pfeffer G, Gan-Or Z, Forkert ND, Monchi O. Sci Rep. 2021;11(1):4917. 
  • Action fluency identifies different sex, age, global cognition, executive function and brain activation profile in non-demented patients with Parkinson’s disease. Auclair-Ouellet N, Hanganu A, Mazerolle EL, Lang ST, Kibreab M, Ramezani M, Haffenden A, Hammer T, Cheetham J, Kathol I, Pike GB, Sarna J, Martino D, Monchi O. J Neurol. 2021;268(3):1036-49.
  • Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders. de Rus Jacquet A, Denis HL, Cicchetti F, Alpaugh M. Mol Psychiatry. 2021. 
  • Multimodal phenotypic axes of Parkinson’s disease. Markello RD, Shafiei G, Tremblay C, Postuma RB, Dagher A, Misic B. NPJ Parkinsons Dis. 2021;7(1):6. 
  • Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson’s Disease. Yu E, Rudakou U, Krohn L, Mufti K, Ruskey JA, Asayesh F, Estiar MA, Spiegelman D, Surface M, Fahn S, Waters CH, Greenbaum L, Espay AJ, Dauvilliers Y, Dupre N, Rouleau GA, Hassin-Baer S, Fon EA, Alcalay RN, Gan-Or Z. Mov Disord. 2021;36(1):178-87. 
  • Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder. Mufti K, Rudakou U, Yu E, Krohn L, Ruskey JA, Asayesh F, Laurent SB, Spiegelman D, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Hogl B, Stefani A, Holzknecht E, Sonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Doring F, Cochen De Cock V, Monaca CC, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Postuma RB, Rouleau GA, Gan-Or Z. Mov Disord. 2021;36(1):235-40. 
  • The Spectrum of Sleep Disorders in Parkinson Disease: A Review. Lajoie AC, Lafontaine AL, Kaminska M. Chest. 2021;159(2):818-27. 
  • The effects of exercise on sleep quality in persons with Parkinson’s disease: A systematic review with meta-analysis. Cristini J, Weiss M, De Las Heras B, Medina-Rincon A, Dagher A, Postuma RB, Huber R, Doyon J, Rosa-Neto P, Carrier J, Amara AW, Roig M. Sleep Med Rev. 2021;55:101384. 
  • A Prodromal Brain-Clinical Pattern of Cognition in Synucleinopathies. Rahayel S, Postuma RB, Montplaisir J, Misic B, Tremblay C, Vo A, Lewis S, Matar E, Ehgoetz Martens K, Blanc F, Yao C, Carrier J, Monchi O, Gaubert M, Dagher A, Gagnon JF. Ann Neurol. 2021;89(2):341-57. 

2020

  • Common and unique connectivity at the interface of motor, neuropsychiatric, and cognitive symptoms in Parkinson’s disease: A commonality analysis. Lang S, Ismail Z, Kibreab M, Kathol I, Sarna J, Monchi O. Hum Brain Mapp. 2020;41(13):3749-64. 
  •  Variants in the Niemann-Pick type C gene NPC1 are not associated with Parkinson’s disease. Ouled Amar Bencheikh B, Senkevich K, Rudakou U, Yu E, Mufti K, Ruskey JA, Asayesh F, Laurent SB, Spiegelman D, Fahn S, Waters C, Monchi O, Dauvilliers Y, Espay AJ, Dupre N, Greenbaum L, Hassin-Baer S, Rouleau GA, Alcalay RN, Fon EA, Gan-Or Z. Neurobiol Aging. 2020;93:143 e1- e4. 
  • Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal. von Linstow CU, Gan-Or Z, Brundin P. Transl Neurodegener. 2020;9(1):39. ??? 
  • Body-first versus brain-first biological subtyping of Parkinson’s disease. Bohnen NI, Postuma RB. Brain. 2020;143(10):2871-3. 
  • Beneficial effects of cysteamine in Thy1-alpha-Syn mice and induced pluripotent stem cells with a SNCA gene triplication. Siddu A, David LS, Lauinger N, Chen X, Saint-Pierre M, Alpaugh M, Durcan T, Cicchetti F. Neurobiol Dis. 2020;145:105042.
  • Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series.  
  • Orthonasal, but not Retronasal Olfaction Is Specifically Impaired in Parkinson’s Disease. Aubry-Lafontaine E, Tremblay C, Durand-Martel P, Dupre N, Frasnelli J. Chem Senses. 2020;45(5):401-6. 
  • The highly selective mGlu2 receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease. Hamadjida A, Sid-Otmane L, Kwan C, Frouni I, Nafade V, Bedard D, Gagnon D, Wallman MJ, Rouillard C, Parent A, Parent M, Huot P. Eur J Neurosci. 2020;51(12):2412-22. 
  • Exercise and Sleep in Parkinson’s Disease. Postuma RB. Mov Disord. 2020;35(6):918-20. 
  • Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease. Goubault E, Bogard S, Blanchet PJ, Bezard E, Vincent C, Martino D, Sarna J, Monchi O, Duval C. Tremor Other Hyperkinet Mov (N Y). 2020;10:20. 
  • Mapping the hyper-direct circuitry of impulsivity. Dagher A. Brain. 2020;143(7):1973-4. 
  • Chronic Neuroleptic-Induced Parkinsonism Examined With Positron Emission Tomography. Galoppin M, Berroir P, Soucy JP, Suzuki Y, Lavigne GJ, Gagnon JF, Montplaisir JY, Stip E, Blanchet PJ. Mov Disord. 2020;35(7):1189-98. 
  • Obstructive Sleep Apnea in Neurodegenerative Disorders: Current Evidence in Support of Benefit from Sleep Apnea Treatment. Lajoie AC, Lafontaine AL, Kimoff RJ, Kaminska M. J Clin Med. 2020;9(2). 
  • Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies. Krohn L, Ozturk TN, Vanderperre B, Ouled Amar Bencheikh B, Ruskey JA, Laurent SB, Spiegelman D, Postuma RB, Arnulf I, Hu MTM, Dauvilliers Y, Hogl B, Stefani A, Monaca CC, Plazzi G, Antelmi E, Ferini-Strambi L, Heidbreder A, Rudakou U, Cochen De Cock V, Young P, Wolf P, Oliva P, Zhang XK, Greenbaum L, Liong C, Gagnon JF, Desautels A, Hassin-Baer S, Montplaisir JY, Dupre N, Rouleau GA, Fon EA, Trempe JF, Lamoureux G, Alcalay RN, Gan-Or Z. Ann Neurol. 2020;87(1):139-53. 
  • Obstructive sleep apnea, CPAP therapy and Parkinson’s disease motor function: A longitudinal study. Meng L, Benedetti A, Lafontaine AL, Mery V, Robinson AR, Kimoff J, Gros P, Kaminska M. Parkinsonism Relat Disord. 2020;70:45-50. 
  • Analysis of common and rare VPS13C variants in late-onset Parkinson disease. Rudakou U, Ruskey JA, Krohn L, Laurent SB, Spiegelman D, Greenbaum L, Yahalom G, Desautels A, Montplaisir JY, Fahn S, Waters CH, Levy O, Kehoe CM, Narayan S, Dauvilliers Y, Dupre N, Hassin-Baer S, Alcalay RN, Rouleau GA, Fon EA, Gan-Or Z. Neurol Genet. 2020;6(1):385. 
  • Dopamine imaging in prodromal Parkinson disease trials: Ready for prime time? Postuma RB. Neurology. 2020;95(23):1029-30. 
  • Monoamine oxidase A inhibition and Parkinson’s disease. Huot P. Neurodegener Dis Manag. 2020;10(6):335-7. 
  • GBA variants in REM sleep behavior disorder: A multicenter study. Krohn L, Ruskey JA, Rudakou U, Leveille E, Asayesh F, Hu MTM, Arnulf I, Dauvilliers Y, Hogl B, Stefani A, Monaca CC, Abril B, Plazzi G, Antelmi E, Ferini-Strambi L, Heidbreder A, Boeve BF, Espay AJ, De Cock VC, Mollenhauer B, Sixel-Doring F, Trenkwalder C, Sonka K, Kemlink D, Figorilli M, Puligheddu M, Dijkstra F, Viaene M, Oertel W, Toffoli M, Gigli GL, Valente M, Gagnon JF, Desautels A, Montplaisir JY, Postuma RB, Rouleau GA, Gan-Or Z. Neurology. 2020;95(8):e1008-e16. 
  • White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson’s Disease. Dadar M, Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB, Collins DL. Mov Disord Clin Pract. 2020;7(6):639-47. 
  • Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Sid-Otmane L, Hamadjida A, Nuara SG, Bedard D, Gaudette F, Gourdon JC, Michaud V, Beaudry F, Panisset M, Huot P. Eur J Pharmacol. 2020;873:172957. 
  • Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Krohn L, Wu RYJ, Heilbron K, Ruskey JA, Laurent SB, Blauwendraat C, Alam A, Arnulf I, Hu MTM, Dauvilliers Y, Hogl B, Toft M, Bjornara KA, Stefani A, Holzknecht E, Monaca CC, Abril B, Plazzi G, Antelmi E, Ferini-Strambi L, Young P, Heidbreder A, Cochen De Cock V, Mollenhauer B, Sixel-Doring F, Trenkwalder C, Sonka K, Kemlink D, Figorilli M, Puligheddu M, Dijkstra F, Viaene M, Oertel W, Toffoli M, Gigli GL, Valente M, Gagnon JF, Nalls MA, Singleton AB, andMe Research T, Desautels A, Montplaisir JY, Cannon P, Ross OA, Boeve BF, Dupre N, Fon EA, Postuma RB, Pihlstrom L, Rouleau GA, Gan-Or Z. Ann Neurol. 2020;87(4):584-98. 
  • Decreased Penetrance of Parkinson’s Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study. Ji S, Wang C, Qiao H, Gu Z, Gan-Or Z, Fon EA, Chan P. Mov Disord. 2020;35(4):672-8. 
  • Theta-Burst Stimulation for Cognitive Enhancement in Parkinson’s Disease With Mild Cognitive Impairment: A Randomized, Double-Blind, Sham-Controlled Trial. Lang S, Gan LS, Yoon EJ, Hanganu A, Kibreab M, Cheetham J, Hammer T, Kathol I, Sarna J, Martino D, Monchi O. Front Neurol. 2020;11:584374. 
  • Validation of an Individualized Measure of Quality of Life, Patient Generated Index, for Use with People with Parkinson’s Disease. Kuspinar A, Mate KKV, Lafontaine AL, Mayo N. Neurol Res Int. 2020;2020:6916135. 
  • Association Between BDNF Val66Met Polymorphism and Mild Behavioral Impairment in Patients With Parkinson’s Disease. Ramezani M, Ruskey JA, Martens K, Kibreab M, Javer Z, Kathol I, Hammer T, Cheetham J, Leveille E, Martino D, Sarna JR, Gan-Or Z, Pfeffer G, Ismail Z, Monchi O. Front Neurol. 2020;11:587992. 
  • Cerebellar Contribution to Motor and Non-motor Functions in Parkinson’s Disease: A Meta-Analysis of fMRI Findings. Solstrand Dahlberg L, Lungu O, Doyon J. Front Neurol. 2020;11:127. 
  • Predicting severity and prognosis in Parkinson’s disease from brain microstructure and connectivity. Abbasi N, Fereshtehnejad SM, Zeighami Y, Larcher KM, Postuma RB, Dagher A. Neuroimage Clin. 2020;25:102111. 
  • Detecting the Cognitive Prodrome of Dementia in Parkinson’s Disease. De Roy J, Postuma RB, Brillon-Corbeil M, Montplaisir J, Genier Marchand D, Escudier F, Panisset M, Chouinard S, Gagnon JF. J Parkinsons Dis. 2020;10(3):1033-46. 
  • The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Gan-Or Z, Rao T, Leveille E, Degroot C, Chouinard S, Cicchetti F, Dagher A, Das S, Desautels A, Drouin-Ouellet J, Durcan T, Gagnon JF, Genge A, Karamchandani J, Lafontaine AL, Sun SLW, Langlois M, Levesque M, Melmed C, Panisset M, Parent M, Poline JB, Postuma RB, Pourcher E, Rouleau GA, Sharp M, Monchi O, Dupre N, Fon EA. J Parkinsons Dis. 2020;10(1):301-13. 
  • Can We Predict the Motor Performance of Patients With Parkinson’s Disease Based on Their Symptomatology? Lebel K, Duval C, Goubault E, Bogard S, Blanchet PJ. Front Bioeng Biotechnol. 2020;8:189. 
  • Mild behavioral impairment in Parkinson’s disease is associated with altered corticostriatal connectivity. Lang S, Yoon EJ, Kibreab M, Kathol I, Cheetham J, Hammer T, Sarna J, Ismail Z, Monchi O. Neuroimage Clin. 2020;26:102252. 

2019

  • Canadian guideline for Parkinson disease. Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Appel-Cresswell S, Kalia SK, Schoffer K, Zurowski M, Postuma RB, Udow S, Fox S, Barbeau P, Hutton B. CMAJ. 2019;191(36):E989-E1004. 
  • The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson’s disease. Yi W, MacDougall EJ, Tang MY, Krahn AI, Gan-Or Z, Trempe JF, Fon EA. Hum Mol Genet. 2019;28(17):2811-25. 
  • Transcranial magnetic stimulation improves cognition over time in Parkinson’s disease. Trung J, Hanganu A, Jobert S, Degroot C, Mejia-Constain B, Kibreab M, Bruneau MA, Lafontaine AL, Strafella A, Monchi O. Parkinsonism Relat Disord. 2019;66:3-8. 
  • Changes in Resting-State Functional Connectivity Related to Freezing of Gait in Parkinson’s Disease. Potvin-Desrochers A, Mitchell T, Gisiger T, Paquette C. Neuroscience. 2019;418:311-7. 
  • Exposure to Pesticides and Welding Hastens the Age-at-Onset of Parkinson’s Disease. Gamache PL, Haj Salem I, Roux-Dubois N, Le Bouthillier J, Gan-Or Z, Dupre N. Can J Neurol Sci. 2019;46(6):711-6. 
  • Cerebral Metabolic Changes Related to Freezing of Gait in Parkinson Disease. Mitchell T, Potvin-Desrochers A, Lafontaine AL, Monchi O, Thiel A, Paquette C. J Nucl Med. 2019;60(5):671-6. 
  • Evaluating the content validity of generic preference-based measures for use in Parkinson’s disease. Kuspinar A, Mate K, Lafontaine AL, Mayo N. Parkinsonism Relat Disord. 2019;62:112-6. 
  • Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine  
  • Brain atrophy in Parkinson’s disease with polysomnography-confirmed REM sleep behavior disorder. Rahayel S, Gaubert M, Postuma RB, Montplaisir J, Carrier J, Monchi O, Remillard-Pelchat D, Bourgouin PA, Panisset M, Chouinard S, Joubert S, Gagnon JF. Sleep. 2019;42(6). 
  • Network basis of the dysexecutive and posterior cortical cognitive profiles in Parkinson’s disease. Lang S, Hanganu A, Gan LS, Kibreab M, Auclair-Ouellet N, Alrazi T, Ramezani M, Cheetham J, Hammer T, Kathol I, Sarna J, Monchi O. Mov Disord. 2019;34(6):893-902. 
  • Evolution of prodromal Parkinson’s disease and dementia with Lewy bodies: a prospective study. Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Brain. 2019;142(7):2051-67. 
  • Parkinson’s disease patients experiencing peak-dose dyskinesia redistribute involuntary movements throughout their body to improve motor control. Lebel K, Duval C, Goubault E, Bogard S, Blanchet PJ. Parkinsonism Relat Disord. 2019;64:312-4. 
  • Algorithmic Complexity of EEG for Prognosis of Neurodegeneration in Idiopathic Rapid Eye Movement Behavior Disorder (RBD).Ruffini G, Ibanez D, Kroupi E, Gagnon JF, Montplaisir J, Postuma RB, Castellano M, Soria-Frisch A.  Ann Biomed Eng. 2019;47(1):282-96. 
  • Prodromal Marker Progression in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Sample Size for Clinical Trials. Alotaibi F, Pelletier A, Gagnon JF, Montplaisir JY, Postuma RB. Mov Disord. 2019;34(12):1914-9. 
  • Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson disease. Yoon EJ, Ismail Z, Hanganu A, Kibreab M, Hammer T, Cheetham J, Kathol I, Sarna JR, Martino D, Furtado S, Monchi O. Neurology. 2019;93(8):e766-e77. 
  • Prodromal Parkinson disease: do we miss the signs? Postuma RB. Nat Rev Neurol. 2019;15(8):437-8. 
  • Glucocerebrosidase mutations and phenoconversion of REM sleep behavior disorder to parkinsonism and dementia. Honeycutt L, Montplaisir JY, Gagnon JF, Ruskey J, Pelletier A, Gan-Or Z, Postuma RB. Parkinsonism Relat Disord. 2019;65:230-3. 
  • A clinical-anatomical signature of Parkinson’s disease identified with partial least squares and magnetic resonance imaging. Zeighami Y, Fereshtehnejad SM, Dadar M, Collins DL, Postuma RB, Misic B, Dagher A. Neuroimage. 2019;190:69-78. 
  • Prospective memory in idiopathic REM sleep behavior disorder with or without mild cognitive impairment: A preliminary study. Marcone S, Gagnon JF, Desjardins C, David AC, Postuma RB, Montplaisir J, Joubert S, Rouleau I. Clin Neuropsychol. 2019;33(3):571-93. 
  • SMPD1 mutations, activity, and alpha-synuclein accumulation in Parkinson’s disease. Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, Ruskey JA, Leblond CS, Ambalavanan A, Laurent SB, Spiegelman D, Dionne-Laporte A, Liong C, Levy OA, Fahn S, Waters C, Kuo SH, Chung WK, Ford B, Marder KS, Kang UJ, Hassin-Baer S, Greenbaum L, Trempe JF, Wolf P, Oliva P, Zhang XK, Clark LN, Langlois M, Dion PA, Fon EA, Dupre N, Rouleau GA, Gan-Or Z. Mov Disord. 2019;34(4):526-35. 
  • Portrait of blood-derived extracellular vesicles in patients with Parkinson’s disease. Lamontagne-Proulx J, St-Amour I, Labib R, Pilon J, Denis HL, Cloutier N, Roux-Dalvai F, Vincent AT, Mason SL, Williams-Gray C, Duchez AC, Droit A, Lacroix S, Dupre N, Langlois M, Chouinard S, Panisset M, Barker RA, Boilard E, Cicchetti F. Neurobiol Dis. 2019;124:163-75. 
  • Remnants of Cardinal Symptoms of Parkinson’s Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living. Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bezard E, Vincent C, Sarna J, Monchi O, Duval C. Front Neurol. 2019;10:256. 
  • Deep Learning With EEG Spectrograms in Rapid Eye Movement Behavior Disorder. Ruffini G, Ibanez D, Castellano M, Dubreuil-Vall L, Soria-Frisch A, Postuma R, Gagnon JF, Montplaisir J. Front Neurol. 2019;10:806. 
  • One Step Into the Future: New iPSC Tools to Advance Research in Parkinson’s Disease and Neurological Disorders. Mohamed NV, Larroquette F, Beitel LK, Fon EA, Durcan TM. J Parkinsons Dis. 2019;9(2):265-81. 
  • Assessment of a prognostic MRI biomarker in early de novo Parkinson’s disease. Zeighami Y, Fereshtehnejad SM, Dadar M, Collins DL, Postuma RB, Dagher A. Neuroimage Clin. 2019;24:101986. 
  • Why Is Aging a Risk Factor for Cognitive Impairment in Parkinson’s Disease?-A Resting State fMRI Study. Nagano-Saito A, Bellec P, Hanganu A, Jobert S, Mejia-Constain B, Degroot C, Lafontaine AL, Lissemore JI, Smart K, Benkelfat C, Monchi O. Front Neurol. 2019;10:267. 
  • Abnormal Muscle Activity and Variability Before, During, and After the Occurrence of Freezing in Parkinson’s Disease. Cantu H, Nantel J, Millan M, Paquette C, Cote JN. Front Neurol. 2019;10:951.